Wolfe starts Inventiva at Outperform on ‘constructive’ lanifibranor view

As previously reported, Wolfe Research initiated coverage of Inventiva (IVA) with an Outperform rating and $13 price target calling the Phase 3 NATiV3 topline readout “the single most important event for the company” expected in the second half of 2026 and telling investors that the firm is “constructive” heading into the data. The firm’s analysis suggests lanifibranor could demonstrate superior fibrosis improvement efficacy over approved MASH therapies, the analyst noted.